Literature DB >> 20352071

Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.

Gianfranco Balboni1, Severo Salvadori, Claudio Trapella, Brian I Knapp, Jean M Bidlack, Lawrence H Lazarus, Xuemei Peng, John L Neumeyer.   

Abstract

Based on a renewed importance recently attributed to bi- or multifunctional opioids, we report the synthesis and pharmacological evaluation of some analogues derived from our lead μ agonist / δ antagonist, H-Dmtn class="Chemical">-Tic-Gly-NH-Bzl. Our previous studies focused on the importance of the C-teminal benzyl function in the induction of such bifunctional activity. The introduction of some substituents in the para position of the phenyl ring (-Cl, -CH(3), partially -NO(2), inactive -NH(2)) was found to give a more potent μ agonist / antagonist effect associated with a relatively unmodified δ antagonist activity (pA(2) = 8.28-9.02). Increasing the steric hindrance of the benzyl group (using diphenylmethyl and tetrahydroisoquinoline functionalities) substantially maintained the μ agonist and δ antagonist activities of the lead compound. Finally and quite unexpectedly D-Tic2, considered as a wrong opioid message now; inserted into the reference compound in lieu of L-Tic, provided a μ agonist / δ agonist better than our reference ligand (H-Dmt-Tic-Gly-NH-Ph) and was endowed with the same pharmacological profile.

Entities:  

Year:  2010        PMID: 20352071      PMCID: PMC2843921          DOI: 10.1021/cn900025j

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  37 in total

1.  Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.

Authors:  Gianfranco Balboni; Valentina Onnis; Cenzo Congiu; Margherita Zotti; Yusuke Sasaki; Akihiro Ambo; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Claudio Trapella; Severo Salvadori
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

2.  2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.

Authors:  Hsu Tsu; Xin Chen; Chiung-Tong Chen; Shiow-Ju Lee; Chung-Nien Chang; Kuo-His Kao; Mohane Selvaraj Coumar; Yen-Ting Yeh; Chia-Hui Chien; Hsin-Sheng Wang; Ke-Ta Lin; Ying-Ying Chang; Ssu-Hui Wu; Yuan-Shou Chen; I-Lin Lu; Su-Ying Wu; Ting-Yueh Tsai; Wei-Cheng Chen; Hsing-Pang Hsieh; Yu-Sheng Chao; Weir-Torn Jiaang
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

3.  5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion.

Authors:  A E Foxx-Orenstein; J G Jin; J R Grider
Journal:  Am J Physiol       Date:  1998-11

4.  Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats.

Authors:  M J Hepburn; P J Little; J Gingras; C M Kuhn
Journal:  J Pharmacol Exp Ther       Date:  1997-06       Impact factor: 4.030

5.  Relative efficacy of the opioid antagonist, naltrexone, on the initiation and promotion phases of rat mammary carcinogenesis.

Authors:  K L Koo; G A Tejwani; H Abou-Issa
Journal:  Anticancer Res       Date:  1996 Jul-Aug       Impact factor: 2.480

6.  Morphine tolerance increases mu-noncompetitive delta binding sites.

Authors:  R B Rothman; J A Danks; A E Jacobson; T R Burke; K C Rice; F C Tortella; J W Holaday
Journal:  Eur J Pharmacol       Date:  1986-05-13       Impact factor: 4.432

7.  Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore.

Authors:  Gianfranco Balboni; Severo Salvadori; Remo Guerrini; Lucia Negri; Elisa Giannini; Yunden Jinsmaa; Sharon D Bryant; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

8.  Naltrexone modulates tumor response in mice with neuroblastoma.

Authors:  I S Zagon; P J McLaughlin
Journal:  Science       Date:  1983-08-12       Impact factor: 47.728

Review 9.  Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.

Authors:  N Dietis; R Guerrini; G Calo; S Salvadori; D J Rowbotham; D G Lambert
Journal:  Br J Anaesth       Date:  2009-05-27       Impact factor: 9.166

10.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.

Authors:  Kalpna Gupta; Smita Kshirsagar; Liming Chang; Robert Schwartz; Ping-Y Law; Doug Yee; Robert P Hebbel
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  20 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

Review 2.  Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Authors:  Melissa L Perreault; Ahmed Hasbi; Brian F O'Dowd; Susan R George
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

3.  Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.

Authors:  Aaron M Bender; Nicholas W Griggs; Jessica P Anand; John R Traynor; Emily M Jutkiewicz; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2015-05-13       Impact factor: 4.418

4.  Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.

Authors:  V Blair Journigan; Willma E Polgar; Taline V Khroyan; Nurulain T Zaveri
Journal:  Bioorg Med Chem       Date:  2014-03-05       Impact factor: 3.641

5.  Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.

Authors:  Henry I Mosberg; Larisa Yeomans; Aubrie A Harland; Aaron M Bender; Katarzyna Sobczyk-Kojiro; Jessica P Anand; Mary J Clark; Emily M Jutkiewicz; John R Traynor
Journal:  J Med Chem       Date:  2013-02-27       Impact factor: 7.446

6.  In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.

Authors:  N Dietis; H Niwa; R Tose; J McDonald; V Ruggieri; M Filaferro; G Vitale; L Micheli; C Ghelardini; S Salvadori; G Calo; R Guerrini; D J Rowbotham; D G Lambert
Journal:  Br J Pharmacol       Date:  2018-05-14       Impact factor: 8.739

7.  Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show in Vitro Kappa and Mu Opioid Receptor Agonism.

Authors:  Deanna Montgomery; Jessica P Anand; Nicholas W Griggs; Thomas J Fernandez; Joshua G Hartman; Ashley A Sánchez-Santiago; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2019-07-01       Impact factor: 4.418

8.  Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction.

Authors:  András Váradi; Travis C Palmer; Nathan Haselton; Daniel Afonin; Joan J Subrath; Valerie Le Rouzic; Amanda Hunkele; Gavril W Pasternak; Gina F Marrone; Attila Borics; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2015-07-21       Impact factor: 4.418

9.  Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain.

Authors:  Nunzio Vicario; Lorella Pasquinucci; Federica M Spitale; Santina Chiechio; Rita Turnaturi; Filippo Caraci; Daniele Tibullo; Roberto Avola; Rosario Gulino; Rosalba Parenti; Carmela Parenti
Journal:  Mol Neurobiol       Date:  2019-04-28       Impact factor: 5.590

10.  Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.

Authors:  Ruben S Vardanyan; James P Cain; Saghar Mowlazadeh Haghighi; Vlad K Kumirov; Mary I McIntosh; Alexander J Sandweiss; Frank Porreca; Victor J Hruby
Journal:  J Heterocycl Chem       Date:  2016-06-01       Impact factor: 2.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.